Vol 94, No 1 (2023)
Other materials agreed with the Editors
Published online: 2023-01-31

open access

Page views 3107
Article views/downloads 448
Get Citation

Connect on Social Media

Connect on Social Media

Molecular classification in endometrial cancer — are we ready?

Agnieszka Rychlik1, Mariusz Bidzinski1
Pubmed: 36748253
Ginekol Pol 2023;94(1):1-2.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Kandoth C, Schultz N, Cherniack AD, et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
  2. Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol. 2016; 143(1): 46–53.
  3. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2): 299–310.
  4. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5): 802–813.
  5. Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015; 28(6): 836–844.
  6. Bayramoglu D, Seçilmiş Kerimoğlu Ö, Bayramoğlu Z, et al. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods. Ginekol Pol. 2022 [Epub ahead of print].
  7. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
  8. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020; 38(1): 1–10.
  9. Oaknin A, Tinker A, Gilbert L, et al. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. JAMA Oncology. 2020; 6(11): 1766.
  10. Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018; 36(20): 2044–2051.
  11. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. International Journal of Gynecologic Cancer. 2022; 33(1): 109–117.
  12. van den Heerik AS, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020; 30(12): 2002–2007.
  13. León-Castillo A, de Boer SM, Powell ME, et al. TransPORTEC consortium. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020; 38(29): 3388–3397.
  14. Bartosch C, Clarke B, Bosse T. Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology. 2018; 50(2): 222–237.
  15. Mur P, García-Mulero S, Del Valle J, et al. Role of POLE and POLD1 in familial cancer. Genet Med. 2020; 22(12): 2089–2100.
  16. Bidzinski M, Danska-Bidzinska A, Rychlik A, et al. Molecular classification of endometrial carcinoma, is it the new era of precision medicine? Ginekologia Polska. 2022; 93(2): 163–167.